A Lifesaving Opportunity
In 2008, Dr. Keith A. Landesman, a beloved son, father, and husband lost his life to cancer. Each year his parents Jane and Richard Landesman of Westport, CT, along with their family and friends, honor his life and legacy by raising funds to support postdoctoral fellows whose groundbreaking research expands our knowledge of cancer and its relationship to the immune system.
This year, you can be a part of this special cause and make a difference in the lives of those affected by cancer by giving to the Keith A. Landesman Memorial Fund.
Donate Online Today
If you wish to mail in a contribution, please make your donation payable to Cancer Research Institute and send to:
Keith A. Landesman Memorial Fund
c/o Cancer Research Institute
29 Broadway, 4th Floor
New York, NY 10006
Landesman Fundraising Events
Why CRI? Why Immunotherapy?
Conquering cancer in our lifetime with immunotherapy will require more research in laboratories and clinics around the world. Your support of the Cancer Research Institute (CRI) will help us get there sooner. CRI pioneered the field of immunotherapy, providing support for researchers since 1953. Today, CRI is leading the way in funding innovative research, fostering scientific collaboration, and educating the public about the power of immunotherapy.
Thanks to decades of research, immunotherapy has become a new way to treat cancer by harnessing our own immune system's innate power to find and eliminate cancer. The FDA has recently approved several immunotherapies for 20 types of cancer. More treatments are in the pipeline for many other types of cancer. Truly, a revolution in cancer treatment has begun.
This year, more than 1.7 million Americans will be diagnosed with cancer, and more than 600,000 will die of cancer. Worldwide, cancer claims the lives of more than 8 million people each year. It's a global health crisis that will worsen unless we do something now to stop cancer in its tracks. By supporting the Keith A. Landesman Memorial Fund, you can help us create a future immune to cancer.